Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism

Summary

The role of C-reactive protein (CRP) in venous thromboembolism (VTE) is still under discussion because of controversial results in the literature. Conflicting data may have partly been due to bias by exogenous factors altering CRP levels. We investigated CRP concentrations in patients with spontaneous VTE applying a study design that allowed the measurement of basal high sensitivity (hs)-CRP levels. Patients with a history of deep vein thrombosis (DVT, n=117) and pulmonary embolism (PE, n=97) were compared to healthy individuals (n=104). Hs-CRP levels (mg/dl) were significantly higher in patients (n=214, median/interquartile range: 0.171/0.082–0.366) than in controls (0.099/0.053–0.245, p=0.001). The unadjusted odds ratio (OR) for VTE per 1 mg/dl increase of CRP was 2.8 [95% confidence interval (CI): 1.1–6.8, p=0.03]. This association remained significant after adjustment for factor V Leiden, prothrombin G20210A and factor VIII activity above 230% (OR = 2.9, 95% CI [1.1–7.5]), but became remarkably attenuated and lost its statistical significance after adjustment for BMI alone (OR = 1.7 [0.7–4.0]). CRP was also not independently associated with VTE in subgroups of patients (those with DVT without symptomatic PE, those with PE and patients without established risk factor) in multiple regression analysis. In summary, we observed significantly higher basal hs-CRP levels in patients with spontaneous VTE compared to healthy controls. This association was independent of hereditary and laboratory risk factors for VTE, but lost its significance after adjustment for BMI. Increased basal CRP levels do not appear to represent an independent risk factor for VTE.

Keywords

Venous thrombosis - pulmonary embolism - C-reactive protein - body mass index

• References

• 1 De Backer J, Mak R, De Bacquer D. et al. Parameters of inflammation and infection in a community based case- control study of coronary heart disease. Atherosclerosis 2002; 160: 457-63.
• 2 Ridker PM, Cushman M, Stampfer MJ. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
• 3 Albert MA. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 2000; 2: 274-9.
• 4 Danesh J, Wheeler JG, Hirschfield GM. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
• 5 Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002; 28: 555-68.
• 6 Visser M, Bouter LM, McQuillan GM. et al. Elevated C-reactive protein levels in overweight and obese adults. Jama 1999; 282: 2131-5.
• 7 Cermak J, Key NS, Bach RR. et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
• 8 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
• 9 Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
• 10 Kamphuisen PW, Eikenboom JC, Vos HL. et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
• 11 Lowe G, Rumley A, Woodward M. et al. C-reactive protein, idiopathic venous thromboembolism and hormone replacement therapy. Thromb Haemost 2000; 84: 730-1.
• 12 Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004; 2: 619-22.
• 13 Tsai AW, Cushman M, Rosamond WD. et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-42.
• 14 Bermudez EA, Rifai N, Buring J. et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668-73.
• 15 Danilenko-Dixon DR, Heit JA, Silverstein MD. et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001; 184: 104-10.
• 16 Akbar D. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine 2003; 20: 215-8.
• 17 Ridker PM, Hennekens CH, Rifai N. et al. Hormone replacement therapy and increased plasma concentration of C- reactive protein. Circulation 1999; 100: 713-6.
• 18 Vukovich TC, Mustafa S, Rumpold H. et al. Evaluation of a turbidimetric Denka Seiken C-reactive protein assay for cardiovascular risk estimation and conventional inflammation diagnosis. Clin Chem 2003; 49: 511-2.
• 19 Pabinger I, Grafenhofer H, Kaider A. et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21: 874-9.
• 20 Hak AE, Stehouwer CD, Bots ML. et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986-91.
• 21 Pannacciulli N, Cantatore FP, Minenna A. et al. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001; 25: 1416-20.
• 22 Weisberg SP, McCann D, Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
• 23 Mohamed-Ali V, Flower L, Sethi J. et al. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 2001; 86: 5864-9.
• 24 Bullo M, Garcia-Lorda P, Megias I. et al. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003; 11: 525-31.
• 25 Moshage HJ, Roelofs HM, van Pelt JF. et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reac tive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988; 155: 112-7.
• 26 Castell JV, Gomez-Lechon MJ, David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988; 232: 347-50.
• 27 Esposito K, Pontillo A, Di Palo C. et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. Jama 2003; 289: 1799-804.
• 28 Tchernof A, Nolan A, Sites CK. et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002; 105: 564-9.
• 29 Kopp HP, Kopp CW, Festa A. et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-7.
• 30 Roumen-Klappe EM, den Heijer M, van Uum SH. et al. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg 2002; 35: 701-6.
• 31 Korte WC, Wuillemin WA, Caliezi C. et al. CRP measured by a high sensitivity assay correlates with clinical probability (Wells score) testing for deep venous thrombosis. Thromb Haemost 2004; 91: 841-2.
• 32 Bucek RA, Reiter M, Quehenberger P. et al. C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol 2002; 119: 385-9.
• 33 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
• 34 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
• 35 Mantilla CB, Horlocker TT, Schroeder DR. et al. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 2003; 99: 552-60. discussion 555A